Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents

@article{Wang2018BlasticPD,
  title={Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents},
  author={Shunan Wang and Xingtong Wang and Mingsuo Liu and Ou Bai},
  journal={Annals of Hematology},
  year={2018},
  volume={97},
  pages={563-572}
}
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematopoietic malignancy mainly affecting elderly patients. Most patients present with asymptomatic skin lesions as the first symptom and has a high frequency of bone marrow involvement. BPDCN is typically characterized by CD4+ and CD 56+ co-expression without common lymphoid or myeloid lineage markers. There is no consensus on the optimal therapeutic strategy for BPDCN. It is highly responsive to chemotherapy but the… 
Blastic Plasmacytoid Dendritic Cell Neoplasm
TLDR
LS-401 has shown potential to provide durable responses even without transplant, and it appears CD123 is the most viable target for BPDCN, and future studies should continue to exploit its expression on BPD CN cells.
A Case Series of Blastic Plasmacytoid Dendritic Cell Neoplasia
TLDR
Two cases of adult BPDCN treated with high dose cytarabine and methotrexate and autologous hematopoietic stem cell transplantation are described, with the first achieving a complete lasting remission, while the second only a transient improvement in skin lesions.
A case series of blastic plasmacytoid dendritic cell neoplasia
TLDR
Two cases of adult BPDCN treated with high dose cytarabine and methotrexate and autologous hematopoietic stem cell transplantation are described, with the first achieving a complete lasting remission, while the second only a transient improvement in skin lesions.
The advances in therapy of blastic plasmacytoid dendritic cell neoplasm
TLDR
While the current standard treatment for BPDCN is acute leukemia-based regimen followed by hematopoietic stem cell transplantation for transplant-eligible patients, there are very promising results for CD123 directed therapies.
Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia
TLDR
A case of BPDCN is described in a 65-year-old female patient with myeloproliferative disorder (essential thrombocythemia) and chronic lymphocytic leukaemia, who continued to deteriorate and died after 4 months from initial diagnosis.
Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report
TLDR
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from a hematopoietic stem cell that is classified as a distinct entity among myeloid neoplasms.
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study
TLDR
A thorough clinical characterization ofastic plasmacytoid dendritic cell neoplasm is provided and the experience on therapeutic approaches to BPDCN is reported.
Diabetic ketoacidosis following PEG-asparaginase therapy
TLDR
A 21-year-old African American female with history of pre-diabetes, and a diagnosis of a rare leukemia, blastic-plasmacytoid dendritic neoplasm, who developed diabetic ketoacidosis (DKA) after the third dose of PEG-asparaginase infusion is reported.
Cladribine‐based salvage regimen‐induced deep remission of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in leukemia phase
TLDR
The patient has relapsed with BPDCN, and targeted therapy could be an option for this specific mutation, and the NGS platform provided more comprehensive information on the sensitivity of the chemotherapy profile.
...
1
2
...

References

SHOWING 1-10 OF 93 REFERENCES
Case of blastic plasmacytoid dendritic cell neoplasm
TLDR
A 56-year-old Japanese man with extensive multi-agent chemotherapy followed by allogeneic stem cell transplantation with a 4-month history of generalized skin lesions is successfully treated and continues to be in remission.
Treatment of blastic plasmacytoid dendritic cell neoplasm.
TLDR
Novel therapies such as SL-401, a diphtheria toxin conjugated to interleukin-3 (IL-3) is commonly overexpressed in BPDCN and other aggressive myeloid malignancies and has shown considerable promise in ongoing clinical trials.
Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
TLDR
Although BPDCN is initially sensitive to conventional chemotherapy regimens, this response is relatively short and long-term prognosis is poor, and novel targeted therapies may improve outcomes for patients with BPD CN.
Blastic Plasmacytoid Dendritic Cell Neoplasm in the Pediatric Population: A Case Series and Review of the Literature
TLDR
These cases contribute to the limited number of pediatric BPDCN cases, thus helping to advance the knowledge toward an optimal treatment protocol for clinical remission.
Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications
TLDR
In contrast to adult cases, in which long-term survival depends on stem cell transplantation in first complete remission, blastic plasmacytoid dendritic cell neoplasms in children are clinically less aggressive.
Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases
TLDR
It is hypothesized that azacitidine might be an effective and tolerable therapy for older BPDCN patients, unfit for curative chemotherapy and HSCT.
Diffuse lung metastases in a child with blastic plasmacytoid dendritic cell neoplasm and review
TLDR
A special case of BPDCN with diffuse nodular lung metastases and a cutaneous lesion is reported, which achieved a dramatic response to non-Hodgkin lymphoma regimen and remained with complete remission for 2 years.
Gemcitabine in Blastic Plasmacytoid Dendritic Cell Neoplasm (CD4+CD56+ hematodermic neoplasm)
TLDR
In patients with relapsed or refractory aggressive non-Hodgkin lymphoma, gemcitabine led to a 20% response rate with median survival of 6 months, and may provide palliative benefit in some patients with blastic plasmacytoid dendritic cell neoplasm.
Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea
TLDR
All patients treated with intensified chemotherapy showed an objective response, but the duration of response was relatively short, and the development of more effective induction as well as consolidation treatment strategy should be warranted to improve this rare disease entity.
...
1
2
3
4
5
...